Baxter International (NYSE:BAX – Get Free Report) had its price target raised by The Goldman Sachs Group from $17.00 to $19.00 in a report released on Friday,MarketScreener reports. The Goldman Sachs Group’s price objective would suggest a potential upside of 10.11% from the stock’s current price.
A number of other equities research analysts have also issued reports on the company. Citigroup cut their price target on Baxter International from $21.00 to $19.00 and set a “neutral” rating for the company in a research note on Wednesday, March 11th. Jefferies Financial Group lowered their price objective on Baxter International from $21.00 to $19.00 and set a “hold” rating on the stock in a research report on Friday, February 13th. Wall Street Zen lowered Baxter International from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Evercore decreased their target price on Baxter International from $23.00 to $22.00 and set an “outperform” rating on the stock in a research note on Monday, April 6th. Finally, Zacks Research cut Baxter International from a “hold” rating to a “strong sell” rating in a report on Friday, April 24th. Two research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus price target of $19.91.
Baxter International Stock Performance
Baxter International (NYSE:BAX – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The medical instruments supplier reported $0.36 EPS for the quarter, beating the consensus estimate of $0.31 by $0.05. Baxter International had a negative net margin of 9.70% and a positive return on equity of 15.65%. The firm had revenue of $2.70 billion for the quarter, compared to the consensus estimate of $2.62 billion. During the same period last year, the firm earned $0.62 EPS. The company’s revenue was up 2.9% on a year-over-year basis. Equities analysts forecast that Baxter International will post 1.91 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Baxter International
Institutional investors have recently bought and sold shares of the business. Dodge & Cox grew its stake in shares of Baxter International by 10.1% in the 3rd quarter. Dodge & Cox now owns 57,396,370 shares of the medical instruments supplier’s stock worth $1,306,915,000 after buying an additional 5,274,750 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Baxter International by 7.8% during the 4th quarter. Geode Capital Management LLC now owns 13,510,205 shares of the medical instruments supplier’s stock valued at $257,174,000 after buying an additional 972,891 shares in the last quarter. Greenhaven Associates Inc. lifted its holdings in shares of Baxter International by 70.0% in the 4th quarter. Greenhaven Associates Inc. now owns 10,693,223 shares of the medical instruments supplier’s stock valued at $204,347,000 after acquiring an additional 4,404,874 shares during the last quarter. Ameriprise Financial Inc. lifted its holdings in shares of Baxter International by 1.3% in the 2nd quarter. Ameriprise Financial Inc. now owns 7,638,629 shares of the medical instruments supplier’s stock valued at $231,304,000 after acquiring an additional 97,687 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its position in Baxter International by 35.6% in the fourth quarter. Russell Investments Group Ltd. now owns 3,410,689 shares of the medical instruments supplier’s stock worth $65,216,000 after acquiring an additional 894,761 shares in the last quarter. Institutional investors own 90.19% of the company’s stock.
Key Stories Impacting Baxter International
Here are the key news stories impacting Baxter International this week:
- Positive Sentiment: Q1 beat on revenue and EPS — Baxter reported $0.36 EPS vs. consensus $0.31 and $2.70B in revenue (vs. $2.62B expected); top-line growth was driven by strong demand in its medical products & therapies unit. Baxter beats quarterly expectations on strong demand for medical devices
- Positive Sentiment: Overseas sales and segment strength supported the beat and were singled out on the call/presentation, which helped push shares higher initially. Baxter International Inc. 2026 Q1 – Results – Earnings Call Presentation
- Neutral Sentiment: Management reiterated its 2026 growth views and emphasized execution improvements—this supports forward confidence but may not be enough to offset near-term margin concerns. Baxter Posts 1Q Loss, Backs 2026 Growth Views
- Neutral Sentiment: Dividend update: Baxter declared a token quarterly dividend of $0.01 per share (annualized yield ~0.2%); modest cash return that is unlikely to drive significant share moves. (No link)
- Neutral Sentiment: Detailed earnings call transcript and slide deck are available for investors who want granular guidance and margin commentary. Baxter International Inc. (BAX) Q1 2026 Earnings Call Transcript
- Negative Sentiment: Margins contracted and net income metrics remain weak — EPS declined year-over-year (from $0.62 to $0.36) and commentary noted margin pressure, which caps enthusiasm despite the beat. BAX Stock Gains on Q1 Earnings & Sales Beat, Margins Contract
- Negative Sentiment: Evercore cut its price target for BAX (while keeping an Outperform rating), signaling analyst caution and likely weighing on the stock. Evercore Cuts Baxter (BAX) Price Target, Keeps Outperform Rating
Baxter International Company Profile
Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.
In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.
See Also
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.
